Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma

Journal of Neuro-Oncology

Volumn 131, Issue 3, 2017, Pages 603-610

  Kalpathy Cramer, Jayashree ^a   Chandra, Vyshak ^a   Da, Xiao ^a   Ou, Yangming ^a   Emblem, Kyrre E ^a,c   Muzikansky, Alona ^b   Cai, Xuezhu ^a   Douw, Linda ^a,d   Evans, John G ^a   Dietrich, Jorg ^b   Chi, Andrew S ^f   Wen, Patrick Y ^e   Stufflebeam, Stephen ^a   Rosen, Bruce ^a   Duda, Dan G ^b   Jain, Rakesh K ^b   Batchelor, Tracy T ^b   Gerstner, Elizabeth R ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anti angiogenesis; Glioblastoma; MRI; Overall survival; Progression free survival; Tivozanib

Indexed keywords

BIOLOGICAL MARKER; PLACENTAL GROWTH FACTOR; TIVOZANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; QUINOLINE DERIVATIVE; TUMOR MARKER; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD LEVEL; BRAIN EDEMA; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; COLON PERFORATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLIOBLASTOMA; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; IMAGE ANALYSIS; MALE; MOLECULAR DYNAMICS; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; RESTING STATE NETWORK; SEIZURE; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME; ANTAGONISTS AND INHIBITORS; BLOOD; BRAIN TUMOR; CLINICAL TRIAL; DIAGNOSTIC IMAGING; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); ORAL DRUG ADMINISTRATION; PATHOLOGY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PHENYLUREA COMPOUNDS; QUINOLINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84995414662     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-016-2332-5     Document Type: Article

References (33)

1. Folkman J (1972) Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175:409–416
2. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841–844. doi:10.1038/362841a0
3. Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298–307. doi:10.1038/nature10144
4. Plate KH, Risau W (1995) Angiogenesis in malignant gliomas. Glia 15:339–347. doi:10.1002/glia.440150313
5. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK (2010) Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28:2817–2823. doi:10.1200/JCO.2009.26.3988
6. Lu-Emerson C, Duda DG, Emblem KE, Taylor JW, Gerstner ER, Loeffler JS, Batchelor TT, Jain RK (2015) Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol 33: 1197–1213. doi:10.1200/JCO.2014.55.9575
7. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740. doi:10.1200/JCO.2008.19.8721
8. Oldenhuis CN, Loos WJ, Esteves B, van Doorn L, Cotreau MM, Strahs AL, den Hollander MW, Gietema JA, de Vries EG, Eskens FA (2015) A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignancies. Clin Colorectal Cancer 14(18–24):e11. doi:10.1016/j.clcc.2014.12.001
9. Mayer EL, Scheulen ME, Beckman J, Richly H, Duarte A, Cotreau MM, Strahs AL, Agarwal S, Steelman L, Winer EP, Dickler MN (2013) A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer. Breast Cancer Res Treat 140:331–339. doi:10.1007/s10549-013-2632-9
10. Nosov DA, Esteves B, Lipatov ON, Lyulko AA, Anischenko AA, Chacko RT, Doval DC, Strahs A, Slichenmyer WJ, Bhargava P (2012) Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma. J Clin Oncol 30:1678–1685. doi:10.1200/JCO.2011.35.3524
11. Eskens FA, de Jonge MJ, Bhargava P, Isoe T, Cotreau MM, Esteves B, Hayashi K, Burger H, Thomeer M, van Doorn L, Verweij J (2011) Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors. Clin Cancer Res 17:7156–7163. doi:10.1158/1078-0432.CCR-11-0411
12. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972. doi:10.1200/JCO.2009.26.3541
13. Gutman DA, Cooper LA, Hwang SN, Holder CA, Gao J, Aurora TD, Dunn WD Jr, Scarpace L, Mikkelsen T, Jain R, Wintermark M, Jilwan M, Raghavan P, Huang E, Clifford RJ, Mongkolwat P, Kleper V, Freymann J, Kirby J, Zinn PO, Moreno CS, Jaffe C, Colen R, Rubin DL, Saltz J, Flanders A, Brat DJ (2013) MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology 267: 560–569. doi:10.1148/radiol.13120118
14. Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, Jain RK (2009) A “vascular normalization index” as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 69:5296–5300. doi:10.1158/0008-5472.CAN-09-0814
15. Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen BR, Loeffler JS, Wen PY, Sorensen AG, Jain RK (2013) Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci USA 110:19059–19064. doi:10.1073/pnas.1318022110
16. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95
17. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK (2009) Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 27:3027–3035. doi:10.1200/JCO.2008.20.9908
18. Duda DG, Willett CG, Ancukiewicz M, di Tomaso E, Shah M, Czito BG, Bentley R, Poleski M, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito P, Clark JW, Jain RK (2010) Plasma soluble VEGFR-1 Is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist 15:577–583
19. Emblem KE, Farrar CT, Gerstner ER, Batchelor TT, Borra RJ, Rosen BR, Sorensen AG, Jain RK (2014) Vessel caliber–a potential MRI biomarker of tumour response in clinical trials. Nat Rev Clin Oncol 11:566–584. doi:10.1038/nrclinonc.2014.126
20. Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Xu J, Liu Q, van den Bent M (2010) A phase III randomized study comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, with lomustine alone in recurrent glioblastoma patients. Ann Oncol 21(Suppl 8):LBA7
21. Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B, van den Bent MJ (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncology 15:943–953. doi:10.1016/S1470-2045(14)70314-6
22. Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, Batchelor TT, di Tomaso E, Duda DG, Munn LL, Fukumura D, Sorensen AG, Jain RK (2009) Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 27:2542–2552. doi:10.1200/JCO.2008.19.9356
23. Stam CJ (2014) Modern network science of neurological disorders. Nat Rev Neurosci 15:683–695. doi:10.1038/nrn3801
24. Aertsen AM, Gerstein GL, Habib MK, Palm G (1989) Dynamics of neuronal firing correlation: modulation of “effective connectivity”. J Neurophysiol 61:900–917
25. Derks J, Reijneveld JC, Douw L (2014) Neural network alterations underlie cognitive deficits in brain tumor patients. Curr Opin Oncol 26:627–633. doi:10.1097/CCO.0000000000000126
26. Douw L, de Groot M, van Dellen E, Aronica E, Heimans JJ, Klein M, Stam CJ, Reijneveld JC, Hillebrand A (2013) Local MEG networks: the missing link between protein expression and epilepsy in glioma patients? Neuroimage 75:195–203. doi:10.1016/j.neuroimage.2013.02.067
27. Harris RJ, Bookheimer SY, Cloughesy TF, Kim HJ, Pope WB, Lai A, Nghiemphu PL, Liau LM, Ellingson BM (2014) Altered functional connectivity of the default mode network in diffuse gliomas measured with pseudo-resting state fMRI. J Neurooncol 116:373–379. doi:10.1007/s11060-013-1304-2
28. Sourbron SP, Buckley DL (2011) On the scope and interpretation of the Tofts models for DCE-MRI. Mag Reson Med 66:735–745. doi:10.1002/mrm.22861
29. Emblem KE, Mouridsen K, Bjornerud A, Farrar CT, Jennings D, Borra RJH, Wen PY, Ivy P, Batchelor TT, Rosen BR, Jain RK, Sorensen AG (2013) Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med 19:1178–1183. doi:10.1038/nm.3289. http://www.nature.com/nm/journal/v19/n9/abs/nm.3289.html-supplementary-information
30. Ou Y, Davatzikos C (2009) DRAMMS: deformable registration via attribute matching and mutual-saliency weighting. Inf Process Med Imaging 21:50–62
31. Ou Y, Akbari H, Bilello M, Da X, Davatzikos C (2014) Comparative evaluation of registration algorithms in different brain databases with varying difficulty: results and insights. IEEE Trans Med Imaging 33:2039–2065. doi:10.1109/TMI.2014.2330355
32. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, Bannister PR, De Luca M, Drobnjak I, Flitney DE, Niazy RK, Saunders J, Vickers J, Zhang Y, De Stefano N, Brady JM, Matthews PM (2004) Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 23(Suppl 1):S208–S219. doi:10.1016/j.neuroimage.2004.07.051
33. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M (2002) Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15:273–289. doi:10.1006/nimg.2001.0978